TAGCyx Biotechnologies focuses on developing high-performance nucleic acid drugs, leveraging their proprietary nucleic acid technology to create candidate compounds with high affinity and specificity for target molecules. Their innovative approach includes the use of Xenoligo® nucleic acid aptamers, which are designed to be chemically synthesized for stable and cost-effective drug production. These aptamers exhibit high stability and can potentially be developed into ready-to-use pre-filled syringes, enhancing patient convenience. The company is actively engaged in various research collaborations, including projects targeting diseases such as thrombotic thrombocytopenic purpura (TTP) and systemic lupus erythematosus, showcasing their commitment to advancing nucleic acid therapeutics.

In addition to their aptamer technology, TAGCyx is exploring the use of PMPC (Poly(2-methacryloyloxyethyl phosphorylcholine)) to improve the pharmacokinetics of their aptamers. PMPC is a biocompatible polymer that mimics cell membrane properties, offering low immunogenicity and the ability to enhance the half-life of aptamers in the bloodstream without compromising their activity. The company has demonstrated that the binding of PMPC to their Xenoligo® aptamers does not alter their efficacy, while also providing a means to control their disposition in the body. This dual approach of utilizing advanced nucleic acid technologies alongside innovative polymer solutions positions TAGCyx at the forefront of biopharmaceutical development.

Japan

TAGCyx’s scientific team has established its proprietary Xenoligo® technology platform, allowing high functional oligonucletide drug discovery. The Xenoligo® platform utilizes genetic alphabet expansion by unnatural base-pairs to generate customized nucleic acid suited for therapeutic applications.

TAGCYX Biotechnologies

Company Details